GLP2R and Crohn disease: Given the enterotrophic and anti-inflammatory effects of GLP2 in preclinical models, and the preferential location of GLP2 receptors within the areas of intestine most affected by Crohn’s disease [18], a clinical trial of Teduglutide in Crohn’s disease was undertaken.